Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- Marvell Technology shares rise on analyst support
Kiniksa (KNSA) PT Raised to $35 at Evercore ISI
October 29, 2024 4:23 PM EDTEvercore ISI analyst Liisa Bayko raised the price target on Kiniksa (NASDAQ: KNSA) to $35.00 (from $30.00) while maintaining a Outperform rating.
The analyst comments "KNSA has a solid Q with $112.2M Arcalyst sales slightly beating consensus of $111.5M. KNSA raised... More



